RLB and Kineta Announce Second Investment
Investment firm RLB Holdings and Seattle-based biotech company Kineta have announced a new investment partnership focused on accelerating development of Kineta’s clinical stage drug candidates. The two drug programs funded by the investment partnership are ShK-186, an immune-sparing targeted therapeutic focused on autoimmune diseases and rOAS, a pan-viral therapeutic aimed at an array of malicious viruses.
7 February 2013•3 mins read
